FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents



      
           
This page is updated frequently with new Rheumatoid Arthritis-related patent applications. Subscribe to the Rheumatoid Arthritis RSS feed to automatically get the update: related Rheumatoid RSS feeds. RSS updates for this page: Rheumatoid Arthritis RSS RSS


Date/App# patent app List of recent Rheumatoid Arthritis-related patents
12/11/14
20140364401
 Antispasmodic 1,2-diols and 1,2,3-triols patent thumbnailAntispasmodic 1,2-diols and 1,2,3-triols
The present invention is directed to pharmaceutical compositions comprising antispasmodic c4-c8aliphatic-1,2-diols and c4-c8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid.
12/11/14
20140363497
 Nanocell drug delivery system patent thumbnailNanocell drug delivery system
Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
12/04/14
20140356437
 Corticosteroids for the treatment of joint pain patent thumbnailCorticosteroids for the treatment of joint pain
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production..
12/04/14
20140356391
 Amino acid sequences for clinical remission of psoriasis and related diseases. patent thumbnailAmino acid sequences for clinical remission of psoriasis and related diseases.
Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of cutaneous leishmaniasis, psoriasis, psoriatic arthritis, rheumatoid arthritis, atopic dermatitis, seborrheic dermatitis and skin papilloma. Also disclosed are nucleic acid sequences encoding such polypeptides, vectors incorporating such nucleic acid sequences, methods for genetically engineering microbial host cells to produce such polypeptides, and such recombinant microbial host cells.
11/27/14
20140349998
 Pyrrolopyrimidines as janus kinase inhiitors patent thumbnailPyrrolopyrimidines as janus kinase inhiitors
The instant invention provides compounds of formula i which are jak3 inhibitors. Specifically, the compounds of formula i are pyrrolo[2,3-d]pyrimidine derivative compounds.
11/27/14
20140349989
 Compounds and therapeutic uses thereof patent thumbnailCompounds and therapeutic uses thereof
The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, t-cell mediated autoimmune disease, ischemia, and complications associated with these diseases and disorders.. .
11/27/14
20140349980
 Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage patent thumbnailDelayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.. .
11/27/14
20140348784
 Compositions and methods for treatment of angiogenesis in pathological lesions patent thumbnailCompositions and methods for treatment of angiogenesis in pathological lesions
Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions.
11/20/14
20140342378
 Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis patent thumbnailPeptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue.
11/20/14
20140341887
 Methods for treating, diagnosing, and monitoring rheumatoid arthritis patent thumbnailMethods for treating, diagnosing, and monitoring rheumatoid arthritis
Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents..
11/13/14
20140336162
Locally administrated low doses of corticosteroids
This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot..
11/13/14
20140336121
Factor h for treatment of rheumatoid arthritis
The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising factor h (fh). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the factor h..
11/13/14
20140336069
Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit
Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.. .
11/13/14
20140335081
Treatment for rheumatoid arthritis
Treatment of rheumatoid arthritis (ra) to provide clinical benefit in patients, including decrease in das28-crp by more than 1.2 and/or improvement determined by acr20, acr50 or acr70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to tyr-leu-asp-phe-gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (gm-csfrα). Use of gm-csfrα inhibitors such as mavrilimumab to enhance clinical benefit in ra patients receiving stable dose of dmards, particularly methotrexate..
11/06/14
20140329815
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
11/06/14
20140329799
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
This invention relates to aminopyrimidinone compounds of formula (i) that are inhibitors of interleukin receptor-associated kinases, in particular irak-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.. .
10/30/14
20140322757
Antibodies that bind colony stimulating factor 1 receptor (csf1r)
Antibodies that bind csf1r are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind csf1r are also provided.
10/30/14
20140322274
Therapeutic agents
A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside gm-1 associated activity in an amount effective to treat the disease.. .
10/30/14
20140322239
Anti-il-6 receptor antibodies and methods of use
The present invention provides anti-il-6r monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.. .
10/30/14
20140322211
Tenascin-c and use thereof in rheumatoid arthritis
The present invention provides a method of determining the rheumatoid arthritis status of a subject, or the progression of rheumatoid arthritis, or the appropriate treatment for a subject with rheumatoid arthritis, comprising the steps of (a) determining the level of tenascin-c in a sample from said subject; and (b) comparing the level of tenascin-c determined in step (a) with one or more reference values. Preferably the rheumatoid arthritis referred to is erosive rheumatoid arthritis.
10/23/14
20140316106
Integrin-blocking polypeptides and uses thereof
A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis.
10/23/14
20140315909
3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h- pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors
Salts thereof, their synthesis, and their use as itk and jak3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention..
10/23/14
20140315889
Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against histone deacetylase (hdac), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against histone deacetylase (hdac) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease..
10/23/14
20140315888
Novel heterocyclic derivatives and their uses
The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type i) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer..
10/23/14
20140314866
Materials and methods for modulating immune responses
The present invention provides nanoparticle-coupled tolerogenic treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (sle), multiple sclerosis (ms), inflammatory bowel disease (ibd), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with graft versus host disease (gvhd) following hematopoietic stem cell transplantation..
10/23/14
20140314741
Human antibody against interleukin-20 and treatment for inflammatory diseases
Flb5m5 is a humanized monoclonal antibody with three mutated amino acids in the cdrs relative to its parental mouse anti-il-20 monoclonal antibody 7e and five mutated amino acids of the light-chain framework region relative to the amino acids of the light-chain framework region of human vκ2. Flb5m5 not only retains binding specificity toward il-20 but also has a better binding affinity than 7e for il-20.
10/09/14
20140303902
Methods, system, and medium for associating rheumatoid arthritis subjects with cardiovascular disease
The present invention relates to a system and a medium for analyzing one or more analytes in rheumatoid arthritis subjects to determine whether the subject is at increased risk of diseases such as a cardiovascular disease, the subject's current cardiovascular disease burden, and the likelihood of cardiovascular disease progression in the subject. In addition, the present invention further provides methods for analyzing data to determine risk of cardiovascular disease, current cardiovascular disease burden, and the likelihood of cardiovascular disease progression in a rheumatoid arthritis subject..
10/09/14
20140303142
Azaindoles as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
10/09/14
20140302053
Compositions for the treatment of rheumatoid arthritis and methods of using same
The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hil-6r) with a dmard.. .
10/02/14
20140294897
Potent lna oligonucleotides for the inhibition of hif-1a expression
The present disclosure relates to an lna oligonucleotide consisting of a sequence selected from the group consisting of 5′-(tx)gxgxcsasasgscsastscscstxgxt-3′ and 5′-(gx)txtxascstsgscscststscstxtxa-3′, wherein capital letters designate a beta-d-oxy-lna nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-d-oxy-lna nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/lna nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/lna nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The lna oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (hif-1a), e.g.
10/02/14
20140294856
Combination treatment comprising a hdac6 inhibitor and an akt inhibitor
The invention provides compositions comprising a histone deacetylase 6 (hdac6) inhibitor and an akt inhibitor, pharmaceutical compositions/formulations and kits of parts comprising the same; optionally further comprising one or more anti-cancer agents. The compositions of the invention provide for surprisingly efficacious killing of inter alia, cancer cells.
09/25/14
20140288011
Genetic association
This invention is directed in part to methods, assays and/or kits for identifying an individual who has an autoimmune disease (such as rheumatoid arthritis), or who has an altered risk for having or developing the autoimmune disease. The methods in one aspect comprise determining the presence or absence of a nucleic acid variant within the somatostatin receptor type 2 (sstr2) gene in the individual's nucleic acids, wherein the presence of the nucleic acid variant is correlated with having the autoimmune disease or the altered risk.
09/18/14
20140277220
Heated garment for medical applications
A patient-treatment system and related method provide relief from, and treatment for, muscle spasticity disorders, willis-ekbom disease, contracture, sleep onset insomnia, sleep maintenance insomnia, rheumatoid arthritis, and other similar disorders by applying controlled heat, and optionally muscle monitoring/stimulation, to one or more parts of a patient's body.. .
09/18/14
20140275203
Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof
The present invention is for method of treating metabolic bone disease, new compounds and pharmaceutical compositions comprising the active ingredients having inhibition effects on osteoclast differentiation. The pharmaceutical composition comprising new compounds according to the present invention can be used as medicines for treating metabolic bone diseases such as bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone, and paget's disease..
09/18/14
20140271645
Method for treating inflammation
A method for treating il-20 induced inflammation. An antagonist to il-20 is administered to treat inflammation and associated diseases.
09/18/14
20140271630
Rituximab induction therapy followed by glatiramer acetate therapy
The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, crohn's disease, or systemic lupus erythematosus..
09/11/14
20140255957
Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.. .
09/11/14
20140255422
Antibodies that bind to il-23
The present invention provides an antibody that binds to the p19 subunit of human il-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.
09/11/14
20140255406
Anti-tnf-anti-il-17 bispecific antibodies
Bispecific antibodies are provided that specifically bind both tumor necrosis factor alpha (tnfα) and interleukin-17 (il-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including rheumatoid arthritis (ra), psoriatic arthritis (psa), and ankylosing spondylitis (as)..
09/11/14
20140255390
Method of treating rheumatoid arthritis with an anti-il-6r antibody
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hil-6r). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (nsaid), a glucocorticoid, a disease-modifying anti-rheumatic drug (dmard), or a tnf-alpha antagonist, t-cell blocker, anti-cd20 antibody, an il-1, jak or il-17 antagonist, or any combination thereof..
09/11/14
20140255310
Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
The present invention relates to methods of using a g protein-coupled receptor (gpcr) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the gpcr couples to gi.
09/04/14
20140249130
Bipyridylaminopyridines as syk inhibitors
The present invention provides novel pyrimidine amines of formula i which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd and rheumatoid arthritis and cancer.. .
09/04/14
20140248265
Therapeutic antibodies binding il 12rbeta1
The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of the heterodimeric il12 receptor (together with il12rβ2 chain) as well as il23 receptor (together with il23rα chain). The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifny production of t cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifny production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
08/28/14
20140243382
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
08/28/14
20140243309
Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/28/14
20140243301
Chlorobis copper (i) complex compositions and methods of manufacture and use
A method of manufacturing an anhydrous copper complex of formula c12h10cicun2o4 and methods of treating neur-muscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, pain, fatigue, sleeplessness, loss of fine motor control, speech loss, inflexibility, alzheimer's, dementia, amyotrophic lateral sclerosis, depression, lyme disease, lyme disease co-infection, gastroparesis (gp), myopathy, chronic inflammation and/or incontinence. The anhydrous copper complex preferably is administered in a pharmaceutical and/or dietary supplement composition of the invention..
08/28/14
20140243290
Aminopyrimidines as syk inhibitors
The present invention provides novel pyrimidine amines of formula (i) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd and rheumatoid arthritis.. .
08/28/14
20140243273
Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
The present invention provides method of treating or lessening the severity of a disease selected from spondyloarthropathy, systemic lupus erythematosus, rheumatoid arthritis, or any combination thereof comprising the administration of a compound of formula i and an optional co-therapy (e.g., chemotherapy agent, dmard, or any combination thereof). The present invention also provides a pharmaceutical composition comprising a compound of formula i, a method of manufacturing a pharmaceutical composition comprising a compound of formula i, and a method of administering a pharmaceutical composition comprising a solid form of a compound of formula i..
08/28/14
20140242170
Corticosteroids for the treatment of joint pain
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production..
08/28/14
20140242073
Cartilage/bone destruction suppressor
An object of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of cartilage or bone seen in rheumatoid arthritis, osteoarthritis, bone metastasis of malignant tumor, or the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against folate receptor β or a complex of the antibody and a biologically or chemically active substance..
08/21/14
20140235888
(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
08/21/14
20140235672
Chromene modulators of chemokine receptor activity
Or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein w1, w2, w3, y, z, r2, r3, r3′ and r4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (i) are disclosed..
08/21/14
20140235641
Pyrazole carboxamides as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/21/14
20140235543
Methods for isolating and using a subset of cd8 t-cells that are resistant to inhibitors
Methods for identifying a subset of cd8 t cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain cd8 t cells expresses elevated levels of scin and/or pla2g4a, with an elevated level indicative of proliferation of the identified cd8 t cells.
08/21/14
20140234291
Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection..
08/21/14
20140234209
Chimeric and humanized anti-histone antibodies
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
08/14/14
20140228358
Acyclic cyanoethylpyrazoles as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/14/14
20140228357
Novel compounds as hif-1alphainhibitors and manufacturing process thereof
The present invention relates to novel compounds as hif-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against hif-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer.
08/14/14
20140228348
Cyanomethylpyrazole carboxamides as janus kinase inhibitors
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/14/14
20140227711
Genotoxicity as a biomarker for inflammation
The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of dna damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation.
08/14/14
20140227303
Methods for diagnosing and monitoring diseases or conditions using disease modified biomolecules and measurement of a functional immune response
Methods and assays for disease prognosis, detection and treatment monitoring are provided. The assays and methods measure functional immune responses to disease modified biomolecules (dmbs) that are characteristic of a disease of interest.
08/07/14
20140221667
Factor viia inhibitor
The present invention relates to novel inhibitors of factors viia, ixa, xa, xia, in particular factor viia, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed..
08/07/14
20140221654
Protease inhibitors
Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.. .
08/07/14
20140221339
Heterocyclic derivative and pharmaceutical drug
Wherein r1 and r2 are the same or different aromatic rings, etc., and ring a is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mpges-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease..
08/07/14
20140220040
Antibodies to lrp6
Anti-lrp6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-lrp6 antibodies can be used to enhance wnt activity and/or antagonize dkk1 activity.
07/31/14
20140212429
Binding members-513
This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (il-1r1). For example, isolated binding members specific for il-1r1 which competes with il-1 and il-1ra for binding to il-1r1 and binds il-1r1 with a kd of 10 pm or less when measured by kinexa™.
07/24/14
20140206694
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
07/24/14
20140206680
Substituted 6-aza-isoindolin-1-one derivatives
Disclosed are compounds of formula 1, and pharmaceutically acceptable salts thereof, wherein g, p, r1, r2, r3a, r4, and r5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of syk is indicated..
07/17/14
20140200635
Phototherapy device
Provided is a phototherapy device which enables a sufficient amount of light to reach a deep tissue to achieve a satisfactory therapy while preventing the increase in the skin temperature of an affected part, and which can achieve a comfortable therapy. The present invention provides a phototherapy device comprising a sheet-like member having a first surface on which an affected part is to be arranged and a surface light source for emitting light toward the sheet-like member, wherein the first surface is formed in an uneven shape so as to provide multiple grooves.
07/17/14
20140200260
Methods for determining and inhibiting rheumatoid arthritis associated with the braf oncogene in a subject
The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the braf oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the braf oncogene; and culturing the sample in the presence of the agent and determining whether braf oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the braf oncogene.. .
07/17/14
20140200245
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..


Popular terms: [SEARCH]

Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.5902

4029

0 - 1 - 72